BCOP Updates 2026: Updates in Lung Cancer
The treatment landscape of lung cancer is constantly evolving to meet the needs of patients. This presentation will provide an overview of selected novel therapies used in both non-small cell and small cell lung cancers. This update will address novel agents targeting non-small cell lung cancer with HER2 mutations, cMET overexpression, NRG1 fusions, and EGFR mutations. It will also cover two phase III trials in the small-cell lung cancer space and also address bispecific antibodies in lung cancer and management of bispecific-related toxicities.
BCOP Updates 2026: Updates in Lung Cancer
Author: Ming-Hei Tai, PharmD, BCOP
Learning Objectives
- Summarize the mechanisms of actions of novel therapies in lung cancer
- Discuss the role of novel therapies in lung cancer
- Define the side effects of novel therapies in lung cancer
- Describe possible adverse event management strategies for novel agents
Get it now!
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.